Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells

PLoS Neglected Tropical Diseases

Volumn 6, Issue 2, 2012, Pages

  Moi, Meng Ling ^a   Lim, Chang Kweng ^a   Chua, Kaw Bing ^b   Takasaki, Tomohiko ^a   Kurane, Ichiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b MINISTRY OF HEALTH   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 3; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTYPE; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; DENGUE VIRUS; HAMSTER; IMMUNOLOGY; PATHOGENICITY; SERODIAGNOSIS; SERUM;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; CRICETINAE; DENGUE VIRUS; HUMANS; MALAYSIA; NEUTRALIZATION TESTS; RECEPTORS, IGG; SERUM;

EID: 84857855597     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001536     Document Type: Article

References (50)

1. World Health Organization (2009) Dengue: Guidelines for diagnosis, treatment, prevention and control. whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf.
2. Srikiatkhachorn A, Gibbons RV, Green S, Libraty DH, Thomas SJ, et al. (2010) Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, 1994-2005. Clin Infect Dis 50: 1135-1143.
3. Barrera R, Delgado N, Jiménez M, Valero S, (2002) Eco-epidemiological factors associated with hyperendemic dengue haemorrhagic fever in Maracay City, Venezuela. Dengue Bull 26: 84-95.
4. Lai PC, Lee SS, Kao CH, Chen YS, Huang CK, et al. (2004) Characteristics of a dengue hemorrhagic fever outbreak in 2001 in Kaohsiung. J Microbiol Immunol Infect 37: 266-270.
5. Dengue Net-WHO Internet-based system for global surveillance of dengue fever and dengue haemorrhagic fever (dengue/DHF). http://apps.who.int/globalatlas/default.asp.
6. Department of Health, Malaysia (2011) (In Malay) Press release: Dengue fever and chikungunya. http://www.moh.gov.my/pr_categories/1/press_releases.
7. Abu Bakar S, Wong PF, Chan YF, (2002) Emergence of dengue virus type 4 genotype IIA in Malaysia. J Gen Virol 83: 2437-2442.
8. Wong SS, Abdul Jamil J, Abu Bakar S, (2007) Antibody neutralization and viral virulence in recurring dengue virus type 2 outbreaks. Viral Immunol 20: 359-367.
9. Fan WF, Yu SR, Cosgriff TM, (1989) The reemergence of dengue in China. Rev Infect Dis Suppl 4: S847-853.
10. Shu PY, Chien LJ, Chang SF, Su CL, Kuo YC, et al. (2005) Fever screening at airports and imported dengue. Emerg Infect Dis 11: 460-462.
11. Zheng K, Zhou HQ, Yan J, Ke CW, Maeda A, et al. (2009) Molecular characterization of the E gene of dengue virus type 1 isolated in Guangdong province, China, in 2006. Epidemiol Infect 137: 73-78.
12. Guzmán MG, Kouri G, Valdes L, Bravo J, Alvarez M, et al. (2000) Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 152: 793-799.
13. Kosasih H, Yusuf H, Sudjana P, Alisjahbana B, Wuryadi S, et al. (2006) Report of four volunteers with primary, secondary and tertiary dengue infections during a prospective cohort study. Dengue Bull 30: 87-92.
14. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, et al. (1984) Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-669.
15. Alvarez M, Rodriguez-Roche R, Bernardo L, Vázquez S, Morier L, et al. (2006) Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg 75: 1113-1117.
16. Tee HP, How SH, Jamalludin AR, Safhan MN, Sapian MM, et al. (2009) Risk factors associated with development of dengue haemorrhagic fever or dengue shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan. Med J Malaysia 64: 316-20.
17. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, et al. (2010) Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. Plos Negl Trop Dis 4: e617.
18. Modhiran N, Kalayanarooj S, Ubol S, (2010) Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis 4: e924.
19. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N, (2010) Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 201: 923-935.
20. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, et al. (2011) An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 85 (1): 410-421.
21. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, (2011) Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary Infection but not in primary infection. J Infect Dis 203: 1405-1414.
22. Klomporn P, Panyasrivanit M, Wikan N, Smith DR, (2011) Dengue infection of monocytic cells activates ER stress pathways, but apoptosis is induced through both extrinsic and intrinsic pathways. Virology 409 (2): 189-197.
23. Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, et al. (2011) Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology 410: 240-247.
24. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. (2009) A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PloS Med 6: e1000171.
25. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, (2010) Discrepancy in neutralizing antibody titers between plaque reduction neutralizing test using FcγR-negative and FcγR-expressing BHK cells. Clin Vac Immunol 17: 402-407.
26. Cardosa MJ, Choo BH, Zuraini I, (1992) A serological study of Japanese encephalitis virus infections in northern Peninsular Malaysia. Southeast Asian J Trop Med Public Health 22: 341-346.
27. Nayar SK, Noridah O, Paranthaman V, Ranjit K, Norizah I, et al. (2007) Co-infection of dengue virus and chikungunya virus in two patients with acute febrile illness. Med J Malaysia 62: 335-336.
28. Chin PS, Khoo AP, Asmah Hani AW, Chem YK, Norizah I, et al. (2008) Acute dengue in a neonate secondary to perinatal transmission. Med J Malaysia 63: 265-256.
29. Ito M, Takasaki T, Yamada K, Nerome R, Tajima S, (2004) Development and evaluation of fluorogenic taqman reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 42: 5935-5937.
30. Moi ML, Takasaki T, Kotaki A, Tajima S, Lim CK, et al. (2010) Importation of dengue virus type 3 to Japan from Tanzania and Côte d'Ivoire. Emerg Infect Dis 16: 1770-1772.
31. Roehrig J, (2007) Guidelines for plaque reduction neutralizing testing of human antibodies to dengue viruses. World Health Organization.whqlibdoc.who.int/hq/2007/who_ivb_07.07_eng.pdf.
32. Kliks S, Nisalak A, Brandt WE, Wahl L, Burke DS, (1989) Antibody dependent enhancement of dengue virus growth in human monocytes as risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444-451.
33. Konishi E, Tabuchi Y, Yamanaka A, (2010) A simple assay system for infection-enhancing and-neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods 163: 360-367.
34. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, et al. (2007) Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. 81: 13325-13334.
35. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, et al. (2008) Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol 80: 134-146.
36. Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep B, Marovich MA, (2011) Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol 85 (4): 1671-1683.
37. Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, et al. (2004) Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 192: 510-519.
38. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, et al. (2011) Intracellular Cytokine Production by Dengue Virus-specific T cells Correlates with Subclinical Secondary Infection. J Infect Dis 203: 1282-1291.
39. World Health Organization (2007) Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. http://whqlibdoc.who.int/hq/2007/who_ivb_07.07_eng.pdf.
40. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197: 823-829.
41. Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ, (2006) Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 80: 10128-38.
42. Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, et al. (2009) Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vac Immunol 16 (2): 285-7.
43. Shanaka WW, Rodrigo I, Alcena DC, Rose RC, Jin X, et al. (2009) An automated Dengue virus microneutralization plaque assay performed in human Fc(gamma) receptor-expressing CV-1 cells. Am J Trop Med Hyg 80 (1): 61-65.
44. Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, et al. (2006) An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods 134 (1-2): 74-85.
45. Kraus Messer W, Haymore LB, de Silva AM, (2007) Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45 (11): 3777-3780.
46. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, et al. (2008) Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 82 (8): 3939-3951.
47. Morens DM, Larsen LK, Halstead SB, (1987) Study of the distribution of antibody-dependent enhancement determinants on dengue 2 isolates using dengue 2-derived monoclonal antibodies. J Med Virol 22: 163-7.
48. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al. (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189: 990-1000.
49. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15 (3): 312-317.
50. Sabin AB, (1952) Research on dengue fever during World War II. Am J Trop Med Hyg 1: 30-50.